KR20040003401A - Preparation and it's method of functional food for male sexual dysfunction - Google Patents
Preparation and it's method of functional food for male sexual dysfunction Download PDFInfo
- Publication number
- KR20040003401A KR20040003401A KR1020020038089A KR20020038089A KR20040003401A KR 20040003401 A KR20040003401 A KR 20040003401A KR 1020020038089 A KR1020020038089 A KR 1020020038089A KR 20020038089 A KR20020038089 A KR 20020038089A KR 20040003401 A KR20040003401 A KR 20040003401A
- Authority
- KR
- South Korea
- Prior art keywords
- weight
- sexual dysfunction
- male sexual
- functional food
- fructus
- Prior art date
Links
- 206010057672 Male sexual dysfunction Diseases 0.000 title claims abstract description 7
- 235000013376 functional food Nutrition 0.000 title abstract description 5
- 238000000034 method Methods 0.000 title abstract description 4
- 239000000203 mixture Substances 0.000 claims abstract description 5
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 7
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 7
- 235000008434 ginseng Nutrition 0.000 claims description 7
- 240000006079 Schisandra chinensis Species 0.000 claims description 5
- 235000008422 Schisandra chinensis Nutrition 0.000 claims description 5
- 210000003056 antler Anatomy 0.000 claims description 5
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims description 4
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims description 2
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims description 2
- 235000009685 Crataegus X maligna Nutrition 0.000 claims description 2
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims description 2
- 235000009486 Crataegus bullatus Nutrition 0.000 claims description 2
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims description 2
- 235000009682 Crataegus limnophila Nutrition 0.000 claims description 2
- 240000000171 Crataegus monogyna Species 0.000 claims description 2
- 235000004423 Crataegus monogyna Nutrition 0.000 claims description 2
- 235000002313 Crataegus paludosa Nutrition 0.000 claims description 2
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims description 2
- 235000016709 nutrition Nutrition 0.000 claims description 2
- 230000035764 nutrition Effects 0.000 claims description 2
- 239000011787 zinc oxide Substances 0.000 claims description 2
- 244000131316 Panax pseudoginseng Species 0.000 claims 1
- 239000013589 supplement Substances 0.000 claims 1
- 239000011716 vitamin B2 Substances 0.000 claims 1
- 235000019164 vitamin B2 Nutrition 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 235000013343 vitamin Nutrition 0.000 abstract description 4
- 239000011782 vitamin Substances 0.000 abstract description 4
- 229940088594 vitamin Drugs 0.000 abstract description 4
- 229930003231 vitamin Natural products 0.000 abstract description 4
- 235000013305 food Nutrition 0.000 abstract description 3
- FODTZLFLDFKIQH-FSVGXZBPSA-N gamma-Oryzanol (TN) Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)O[C@@H]2C([C@@H]3CC[C@H]4[C@]5(C)CC[C@@H]([C@@]5(C)CC[C@@]54C[C@@]53CC2)[C@H](C)CCC=C(C)C)(C)C)=C1 FODTZLFLDFKIQH-FSVGXZBPSA-N 0.000 abstract description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 abstract description 3
- 239000011707 mineral Substances 0.000 abstract description 3
- 150000003722 vitamin derivatives Chemical class 0.000 abstract description 3
- 239000000843 powder Substances 0.000 abstract description 2
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- 241000007126 Codonopsis pilosula Species 0.000 abstract 1
- 235000008216 herbs Nutrition 0.000 abstract 1
- 201000001881 impotence Diseases 0.000 description 14
- 208000010228 Erectile Dysfunction Diseases 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 10
- 230000000694 effects Effects 0.000 description 8
- 210000002460 smooth muscle Anatomy 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 210000005226 corpus cavernosum Anatomy 0.000 description 7
- 210000003899 penis Anatomy 0.000 description 7
- 241000208340 Araliaceae Species 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 241000411851 herbal medicine Species 0.000 description 6
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 235000015961 tonic Nutrition 0.000 description 5
- 230000001256 tonic effect Effects 0.000 description 5
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 241000282994 Cervidae Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000001568 sexual effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 235000015468 Lycium chinense Nutrition 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 201000001880 Sexual dysfunction Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 235000013527 bean curd Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 210000004209 hair Anatomy 0.000 description 2
- 239000005445 natural material Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical group CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 231100000872 sexual dysfunction Toxicity 0.000 description 2
- 230000000391 smoking effect Effects 0.000 description 2
- 229960000716 tonics Drugs 0.000 description 2
- 210000003708 urethra Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 description 1
- -1 25mM Chemical compound 0.000 description 1
- 206010000372 Accident at work Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010062542 Arterial insufficiency Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000208671 Campanulaceae Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010050403 Carotid artery dissection Diseases 0.000 description 1
- 241000756943 Codonopsis Species 0.000 description 1
- 241000357622 Codonopsis javanica Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 244000241838 Lycium barbarum Species 0.000 description 1
- 235000015459 Lycium barbarum Nutrition 0.000 description 1
- 244000241872 Lycium chinense Species 0.000 description 1
- 241000218377 Magnoliaceae Species 0.000 description 1
- 208000029578 Muscle disease Diseases 0.000 description 1
- 206010029333 Neurosis Diseases 0.000 description 1
- 206010052004 Organic erectile dysfunction Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 240000007711 Peperomia pellucida Species 0.000 description 1
- 235000004347 Perilla Nutrition 0.000 description 1
- 244000124853 Perilla frutescens Species 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 206010052005 Psychogenic erectile dysfunction Diseases 0.000 description 1
- 241000282374 Puma concolor Species 0.000 description 1
- 235000011034 Rubus glaucus Nutrition 0.000 description 1
- 244000235659 Rubus idaeus Species 0.000 description 1
- 235000009122 Rubus idaeus Nutrition 0.000 description 1
- BNRNXUUZRGQAQC-UHFFFAOYSA-N Sildenafil Natural products CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 229960000711 alprostadil Drugs 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000001856 erectile effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 244000237330 gutta percha tree Species 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000031424 hyperprolactinemia Diseases 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000004185 hypothalamic-pituitary-gonadal axis Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 229940028444 muse Drugs 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 208000015238 neurotic disease Diseases 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 150000002926 oxygen Chemical class 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000001734 parasympathetic effect Effects 0.000 description 1
- 210000003049 pelvic bone Anatomy 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 208000022821 personality disease Diseases 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 206010036596 premature ejaculation Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- DEIYFTQMQPDXOT-UHFFFAOYSA-N sildenafil citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 DEIYFTQMQPDXOT-UHFFFAOYSA-N 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000015096 spirit Nutrition 0.000 description 1
- 230000007103 stamina Effects 0.000 description 1
- 208000023516 stroke disease Diseases 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 229960000340 thiopental sodium Drugs 0.000 description 1
- AWLILQARPMWUHA-UHFFFAOYSA-M thiopental sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC([S-])=NC1=O AWLILQARPMWUHA-UHFFFAOYSA-M 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000006492 vascular dysfunction Effects 0.000 description 1
- 229940094720 viagra Drugs 0.000 description 1
- YEFOAORQXAOVJQ-UHFFFAOYSA-N wuweizischun A Natural products C1C(C)C(C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-UHFFFAOYSA-N 0.000 description 1
- 235000016804 zinc Nutrition 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
· 본 발명은 구기자, 산사자, 복분자, 오미자, 녹용, 인삼 등천연물질을일정비율로 혼합하여 남성의 발기부전, 조루증 등 성기능장애에 도움을 줄 수 있는기능성영양보충용 식품의 제조 방법에 관한 것입니다.The present invention relates to a method for producing a functional nutritional supplement food that can help sexual dysfunction, such as erectile dysfunction, premature ejaculation, by mixing natural substances such as wolfberry, mountain lion, bokbunja, Schisandra chinensis, antler, ginseng in a constant ratio .
발기 기능장애는 일반적으로 남성의 성적 기능성 발기 무능력인 발기부전(Erectile dysfunction)을 지칭한다. 발기부전증은 여성의 성문을 열고 들어갈 만한 남성에 힘이 없거나 여성의 성문을 열고 들어갔다고 하더라도 힘이 부쳐 질내 삽입에 충분한 강직도가 형성되지 않아 사정할 때까지 성기의 발기 상태를 충분히 유지하지 못하는 증상이다.Erectile dysfunction generally refers to erectile dysfunction, which is the sexually functional impotence of men. Erectile dysfunction is a condition in which a man who does not have enough strength to enter a woman's gate and / or enters a woman's gate does not maintain sufficient erectile state until the ejaculation due to strength and insufficient rigidity for vaginal insertion.
발기부전증은 성교에 충분한 발기력 및 그 유지력의 불능상태를 의미한다. 음경 중심부분의 특정조직(해면체)이 피로 충혈 됨으로써 음경이 발기된다. 국내발기부전 환자에 대하여 정확한 통계가 없지만 남성 중 약 200만 명 내외가 미국의 경우 18내지 75세의 남성들중 약 1,000만 내지 1,200만 명이 만성발기부전증을 앓고 있으며, 대다수는 55세 이상인 것으로 알려져 있다. 당뇨, 고혈압과 같은 성인병의 증가,스트레스,산업재해 음주, 흡연 등으로 누구든지 성기능 장애의 가능성이 있으므로 예방은 매우 중요하다.Erectile dysfunction means an impotence sufficient for sexual intercourse and an inability to maintain it. The penis is erected by the congestion of certain tissues (cavernous bodies) in the central part of the penis with blood. Although there are no accurate statistics on domestic erectile dysfunction patients, about 2 million men in the US have about 10 million to 12 million men between 18 and 75 years of age, and the majority are over 55 years old. have. Prevention of the disease is very important because of the increase in adult diseases such as diabetes, hypertension, stress, industrial accidents, drinking, smoking, etc.
발기부전증은 심리적 장해(심인성), 생리학적 이상(기질성) 또는 이들 두 가지 복합요인으로 인해 발생된다. 통상적으로 여러 가지 요소가 발기부전증의 원인이 된다.Erectile dysfunction is caused by psychological disorders (psychopathic), physiological abnormalities (stromal), or a combination of both. Typically, many factors contribute to erectile dysfunction.
심인성 발기부전증은 심리적으로 불안하거나 우울증, 정신분열증, 인격장애 등 다양한 신경증적 장애에 있는 남성에게 나타날 수 있으며 성기 능에 대한 잘못된 정보나 무의식적인 죄의식을 갖거나 상대방을 즐겁게 하는데 만 지나치게 관심을 쏟는 경우발생하는 것으로 알려져 있다.Psychogenic erectile dysfunction can occur in men who are psychologically anxious or in various neurotic disorders such as depression, schizophrenia, or personality disorder, and develop when they have misinformation about sexual function, unconscious guilt, or excessive attention only to entertain the person. It is known.
기질성 발기부전증의 중요한 원인으로는 혈관이상, 신경결함(neurologic dificienci 및 약물치료부작용이 있다. 발기부전의 1차적인 혈관원인은 음경이 혈액으로 지는 것을 방해하는 동맥부전중 및 발기가 되여 있는 동안 음경 내에 혈액이 유지되는 것을 방해하는 정맥 이상증이다. 동맥부전증은 1차적으로 동맥경화증에 기인하여흡연,과지방혈증, 만성고혈압, 당뇨병, 관상동맥질환 등이 원인이다. 또한 정맥성 발기 부전증은 음경해면체에 해부학적으로 섬유조직이 증식되거나 평활근육질환, 고원질(collagen)의 변화 등 복합작용에 의해 이중 어느 하나에 이상이 있으면 정맥의 폐쇄기능이 장애를 일으켜 해면체내에 혈액을 저장하지 못하므로 발생되는 것으로 알려져있다.Important causes of organic erectile dysfunction include vascular dysfunction, neurologic dificienci and drug therapy. The primary cause of erectile dysfunction is during arterial failure and erection, which prevents the penis from turning to blood. Arterial insufficiency is primarily due to arteriosclerosis, which is caused by smoking, hyperlipidemia, chronic hypertension, diabetes, and coronary artery disease. If any one of these abnormalities occurs due to the multiplication of fibrous tissue anatomically, smooth muscle disease, collagen changes, etc., the vein occlusion function is disturbed and blood is not stored in the cavernous body. It is known to be.
또한 시상하부-뇌하수체-성선 축의 이상, 고프로락틴혈증, 갑상선, 부심질환, 칼슘대사이상 과 같은 내분비성 이 상시에도 원인이 된다.In addition, endocrine disorders such as hypothalamic-pituitary-gonadal axis, hyperprolactinemia, thyroid, parasympathetic disease, and calcium metabolic abnormalities are also causes.
지금까지 발기부전치료제는 프로스타그란딘E1제제로 미국업론사의 카버젝트(coverject)가 있으며 이 제제는 혈관 확장제로 음경해면체에 직접 주사하여 음경 평활 근을 이완시켜 발기를 유발시키는 것으로 효과면 에서는 확실하나 투여방법이 주사제로 주사에 대한 기피, 음경조직 손 상등의 부작용이 있다.Until now, the erectile dysfunction treatment agent is prostaglandin E1, which is a carbject of American Upron, which is directly injected into the corpus cavernosum to relax the penis smooth muscle, causing erection. The method has side effects such as avoiding injections and penile tissue damage.
한국 얀센(주)사의 뮤즈(muse)는 요도주입식 발기부전치료제로 좌약형이고 요도에만 삽입하는 형태로서 요도주입식은 음경에만 극소적 작용하므로 삽입후 95%이상이 타부위를 거치지 않고 폐로 직접 들어가 폐를 통해 신속히 소실 되여 두통,피부발작, 소화불량, 변비 등의 부작용이 적은 반면 요도의 통증과 작열감이 있고 요도에 직접 집어 넣는다는 점에서 거부감을 느낄 수 있으며 자가 주입한 뒤 약 5분간 마사지가 필요하다는 단점이 있다.Muse of Janssen Co., Ltd. is a urethral injection erectile dysfunction treatment that is suppository and inserted only in the urethra. The urethral injection acts only on the penis. It quickly disappears and has fewer side effects such as headache, skin seizures, indigestion, constipation, while the pain and burning of the urethra can be felt. The disadvantage is that.
미국 화이자사의 비아그라(viagra)는 경구복용으로 간편하여 cGMP의에 관여하는 포스포다이에스터라제(phosphodiesterase)를 억제하여 세포내 cGMP를 증가시켜 음경 해면체의 발기를 유지하나 심장병 환자에게는 혈압이 떨어져 심장마비로 사망 할 가능성이 높아 심근경색, 뇌졸증, 심혈관계질환 환자에 대한 부작용의 문제점이 있다.Viagra, a Pfizer company in the United States, is convenient for oral administration.It suppresses phosphodiesterase, which is involved in cGMP, and increases intracellular cGMP to maintain the erection of penile cavernous bodies. There is a high risk of death due to side effects for patients with myocardial infarction, stroke, and cardiovascular disease.
그 외에도 최근 생약제제로 에스-에스크림을 비롯하여 여러 가지가 있으나 안전하면서도 복용이 간편한 제제는 아직 소개된바 없었다.In addition, there are a number of herbal medicines, such as S-escrim recently, but a safe and easy to take formulation has not been introduced yet.
따라서 본 발명은 부작용이 없으면서 복용이 간편한 성기능 장애에 효과적인 제제를 개발하고 본 발명을 완성하였다.Therefore, the present invention has developed an effective formulation for sexual dysfunction easy to take without side effects and completed the present invention.
본 발명의 목적은 남성 성기능 장애에 대하여 탁월한 치료효과가 있을 뿐 아니라 가능한 한 인체에 안정한 것으로 알려진 생약 즉 천연물질을 원료로 하고 경구투여로 복용이 간편하면서도 효과적인 제제를 개발하므로 써 기존의 양약치료제에서 나타났던 부작용이 전혀 없는 남성성기능 장애 기능성 식품 및 그 제조방법을 제공하기위함이다.The purpose of the present invention is not only to have an excellent therapeutic effect against male sexual dysfunction, but also to develop a medicine that is known to be as stable to the human body as possible as a raw material, a natural substance, and easy to take by oral administration. To provide a male functional dysfunction functional food and a method of manufacturing the same that have no side effects.
본 발명의 남성 성기능장애에 효과적인 제제는 구기자, 산사자, 복분자, 오미자,녹용 만삼, 두충의 7종의 생약과 아연 감마오리자놀과 비타민 미네랄을 함유하는캅셉제이다.The agent effective for male sexual dysfunction of the present invention is a capsule containing 7 kinds of herbal medicines of goji, hawthorn, bokbunja, Schisandra chinensis, antler ginseng, tofu and zinc gamma-orizanol and vitamin minerals.
이하 본 발명의 생약 각 성분에 대한 상세한 설명을 한다.Hereinafter, a detailed description of each herbal ingredient of the present invention.
구기자(拘杞子, chinese matrimony vine)는 구기나무의 열매로 눈을 밝게 하고 젊을을 유지시켜주며 장수하는 약재로 사용된다. 최근 연구결과는 향전작용, 항암,면역증진 간기능개선 및 혈압강하작용 등의 연구가 발표되었으며 신진대사를 촉진시켜주는 자양강장제로 이용되는 생약의 일종이다.Goji (Chinese matrimony vine) is the fruit of the Goji tree to brighten the eyes, keep young and are used as a medicine for longevity. Recent research results have been published in studies on the improvement of anticancer, anti-cancer, immune enhancing liver function and blood pressure lowering, and is a kind of herbal medicine used as a nourishing tonic to promote metabolism.
산사자(山査子)는 산딸기를 한방에서는 복분자라하여 신정(腎精)을 더해주고 소변을 보는데 이롭게 해주며 맛이 달고 신정(腎정)을 보익(보益)하여 여자의 잉태를 돕고 남자의 음위를 강하게 하며 간을 보하고 눈을 밝게 하는 생약의 일종이다Sansa is a raspberry in Chinese medicine, which adds new spirits and benefits to urinate, tastes sweet, and complements women's condolences, helping women conceive and man's genitalia. It is a kind of herbal medicine that strengthens the liver and brightens the eyes.
오미자(五味予)schizandra chinensis) 목련과의 낙엽덩굴식물로서 잎은 타원형 긴 타원형의 모양이면 뒷면 잎맥위에는 털이 있고 가장자리는 톱니모양이며 열매는 둥글고 이삭모양이다. 오미자는 신맛, 단맛, 쓴맛, 짠맛, 매운맛의 다섯 가지 맛이 섞여 있 오미자라 하며 자양, 강장, 거담, 진한 등에 사용하는 생약의 일종이다.Schizandra chinensis is a deciduous plant of the Magnoliaceae. Leaves are oval-shaped, long oval, with hairs on the leaf veins of the back, serrated at the edges, and round and ears. Schisandra chinensis is a combination of five flavors: sour, sweet, bitter, salty, and spicy. It is a kind of herbal medicine used for nourishment, tonic, expectoration, and thickening.
녹용(廬茸)은 그늘에서 말린 사슴의 뿔로서 체력의 증과과 체내의 면역증대 효과와 기(氣)와 혈(血)이 허약한 증상에 사용하며 정력제로 이용되는 생약의 일종이다.Deer antler is a horn of a deer that is dried in the shade. It is a kind of medicinal herb that is used for the increase of physical strength, the effect of increasing the immune system, and the weakness of Gi and blood.
인삼(人蔘 ,codonopsis pilosule)도라지과에 속한 다년생 만초의 뿌리를 만삼이라 하며 일명 당삼더덕이라고도 한다. 인삼대동으로 사용하며 주로 철분을 보하는데 쓰고 허약체질에 좋으며 식용증진, 강장, 보익에 사용되는 생약의 일종이다.Ginseng (人 생, codonopsis pilosule) is the root of perennial perilla belonging to the bellflower family called ginseng, also known as Dangsam Deodeok. Used as ginseng Daedong, it is mainly used to protect iron and is good for weak constitution. It is a kind of herbal medicine used for edible promotion, tonic and bowel.
두충(Eucommia ulmoides)는 두충과 식물로서 잎은 타원형으로 끝이뾰족하며 잔털이 많고 건강차로 이용되며 나무껍질은 보약, 강장제,정력감퇴예방에 이용되고 신경통, 음습증에 사용되는 생약이다.Eucommia ulmoides is a larvae and plant with leaves oval, sharp in tip, with a lot of fine hairs, and used as a health tea. Bark is used as a medicine for tonics, tonics, stamina reduction, neuralgia, and hygropathy.
본 발명의 남성성기능장애 특수영양보충용 식품의 제조방법은The method for producing a food for supplemental nutrition for male sexual dysfunction of the present invention is
구기자 10∼20% 산사자 5∼10% 복분자 5∼10% 오미자 5∼10% 두충 5-15% 혼합한 후 100℃에서 8시간 열두 추출을 후 추출한 액은 농축하여 고형분 50%엑기스로 농축한 후 건조 분말화한 후 만삼 1∼5% 녹용 2∼5%은 따로 주정에 저온추출후 건조 분말한 후 산화아연, 비타민, 감마오리자놀을 혼합하여 캅셀화 하여 제조 하였다.Gojija 10-20% Sansa 5-10% Bokbunja 5-10% Schisandra chinensis 5-10% Tofu 5-15% After mixing for 12 hours at 100 ° C, the extracted solution was concentrated and concentrated to 50% solids. After drying powdered ginseng 1-5% deer antler 2-5% separately extracted at low temperature in alcohol and dried powder, and then the zinc oxide, vitamins, gamma olizanol was prepared by mixing the capsules.
본 발명을 구성하는 기능성 식품을 위하여 약리시험은 음경해면체 평활근의이완효과로 측정 하였으며 다음과 같이 시험을 행하였다.The pharmacological test for the functional food constituting the present invention was measured by the relaxation effect of the corpus cavernosum smooth muscle, and the test was carried out as follows.
· 본 발명에서는 2.5∼3.0kg의 뉴질랜드 화이트계 흰 수컷 토끼 15마리 이용하여 조직을 준비하였다. 티오펜탈 소디움(30mg/kg)을 토끼 귀 정맥에 주사하여 마취시킨 후 음경전체를 골반 골로부터 분리하였고, 해면체조직을주변의 백막에서 분리하였다. 이때 해면체에 존재하는 내피의 손상을 막기 위하여 조직을 무리하게 조작하지 않도록 하였다. 분리된 해면체 평활근에서 두 개의 긴 조직절편(1×2×7mm)을 얻었다. 각각의 절편은 6-0 실을 이용하여 양쪽 끝을 고정한 후 한쪽은 장력을 측정하기 위한 transducer(Grass Research Polygraph, Model 79H, W, Warwick, Ri)에 연결되는 고리에 연결하였고,다른 한쪽은 organ bath의 끝에 고정하였다. 조직을 고정하는 동안 내피조직이 손상되지 않도록 과도하게 잡아당기는 일을 피하였다.In the present invention, tissues were prepared using 15 New Zealand white male rabbits weighing 2.5 to 3.0 kg. Thiopental sodium (30 mg / kg) was injected into the rabbit ear vein, followed by anesthesia, and the whole penis was separated from the pelvic bone, and the cavernous tissue was separated from the surrounding white film. At this time, in order to prevent damage to the endothelium present in the cavernous body was not forced to manipulate the tissue. Two long tissue sections (1 × 2 × 7 mm) were obtained from the separated cavernous smooth muscle. Each section was secured at both ends using a 6-0 thread, and then one was connected to a ring connected to a transducer (Grass Research Polygraph, Model 79H, W, Warwick, Ri) for measuring tension, and the other organ. Fixed at the end of the bath. Avoid excessive pull to avoid damaging the endothelial tissue during fixation.
· 흰 수컷 토끼의 음경 해면체조직의 절편은 5mL의 organ bath에 수직으로 위치시켯고, 조직에서 발생한 장력은 피지오그라피 용지에 기록하였다. 이때 사용한 용액은 HEPES이며, 조성은 NaCl 118mM, KCI 4.7mM, CaCe 2.5mM, MgCl2 2mM, NaHCO3, 25mM, 포도당 10mM, HEPES 10mM이며, 1N NaOH를 이용하여 PH를 7.4로 맞추었다. 실험하는 동안 100% 산소를 이용하였고, organ bath의 온도는 37℃도 맞추었다.Sections of the corpus cavernosum tissue of white male rabbits were placed vertically in a 5 mL organ bath, and the tension in the tissues was recorded on the physicograph paper. The solution used was HEPES, the composition is NaCl 118mM, KCI 4.7mM, CaCe 2.5mM, MgCl2 2mM, NaHCO3, 25mM, glucose 10mM, HEPES 10mM, pH was adjusted to 7.4 using 1N NaOH. 100% oxygen was used during the experiment, and the temperature of the organ bath was set at 37 ° C.
· 상기 해면체조직은 처음에 1g으로 기본장력을 맞추었으며, 약 60분간 기다려 안정화가 된 후 실험을 하였다. 매 15분마다 산소가 포화된 용액으로 바꾸어 주었으며, 실험이 시작되기 전까지 기본장력을 1g이 되도록 다시 조정하였다.The cavernous tissue was initially adjusted to a basic tension of 1 g, and then tested after waiting for about 60 minutes to stabilize. Every 15 minutes, the solution was changed to a saturated oxygen solution, and the basic tension was adjusted to 1 g until the experiment was started.
실험 중 장력의 변화는 피지오그라피 용지에 기록하였다. 약물의 투여는 낮은 농도로부터 높은 농도로 축적하는 방식으로 하였으며, 최고의 이완점에 도달했을 때 다음 농도의 약물을 투여는 낮은 농도로부터 높은 농도로 축적하는 방식으로 하였으며, 최고의 이완점에 도달했을 때 다음 농도의 약물을 투여하였다. 관류용액(상기 Hepes solution을 말함)을 바꾼 후 새로운 약물을 투여할 때는 조직의 안정화를 위하여 약 5∼10분정도 기다렸다.Changes in tension during the experiments were recorded on the physiographies. Drug administration was achieved by accumulating from low to high concentrations, and when the highest relaxation point was reached, administration of the next concentration of drug was achieved by accumulating from low concentration to high concentration, and when the highest relaxation point was reached. Concentration of drug was administered. After changing the perfusion solution (referring to the Hepes solution), when the new drug was administered, the patient waited about 5 to 10 minutes to stabilize the tissue.
1) 실험방법1) Experiment Method
① 체중 2.5∼3kg의 뉴질랜드산 흰색 수컷 가토를 온도 23±℃,상대습도 55±5% 명암교대 12시간으로 사육하였다. 물과 사료는 자유롭게 섭취할 수 있도록 공급하였다.① New Zealand white male rabbits weighing 2.5-3 kg were reared at a temperature of 23 ± ℃ and a relative humidity of 55 ± 5% for 12 hours. Water and feed were provided for free intake.
② 토끼를 고정대위에 올려놓고 사지와 머리를 고정시킨다.② Put the rabbit on the stand and fix the limbs and head.
③ 토끼에게 펜토바바탈 소디움(Pentobarbitel sodim)을 30-50mg/kg)을 정맥주사허여 치사시킨후 경동맥을 절개하여 실험한다.③ Inject rabbits with pentobarbitel sodim (30-50mg / kg) and let them die before carotid artery dissection.
④ 음경을 적출하고 Autostsis를 방지하기 위해 적출즉시 37-38℃의 hepes완충 tyroide 용액내에 보관한다.④ Extract the penis and store it in hepes buffer tyroide solution at 37-38 ℃ immediately to prevent autostsis.
⑤ 현미경을 이용하여 음경해면체의 평활근 절편(6mm × 2mm × 2mm)을 제작함⑤ A smooth muscle slice (6mm × 2mm × 2mm) of the corpus cavernosum was produced using a microscope.
⑥ organ chawber에 37-38℃의 hepes완충 tyroide 용액을 채운후 95%의 산소와 5%의 이산화탄소 가스를 공급해 주면서 37℃의 온수건에 담가 온도를 유지시킨다.⑥ Fill the organ chawber with 37-38 ℃ hepes buffer tyroide solution and supply it with 95% oxygen and 5% carbon dioxide gas to keep the temperature in 37 ℃ hot water gun.
⑦ 음경해면체 평활근 · 질편에 force transducer와 phtsiography를 연결한다.⑦ corpus cavernosum smooth muscle · vaginal connect the force transducer and phtsiography.
⑧ 수축제 (Norepinephrine)를 기하여 인위적으로 수축시킨후 인완제(Acetylcholine) 에 대한 이완반응이 관찰 되는지를 확인하여 해면체 절편의 손상이 없다는 것을 확인후 실험을 진행하였다.⑧ After the artificial contraction by the contractor (Norepinephrine), the experiment was carried out after confirming that there was no damage of the cavernous fragment by confirming that the relaxation reaction to the acetylcholine was observed.
⑨ 이완효과 측정⑨ Measure relaxation effect
가. 음경해면체 평활근에 수축제를 가하여 수축시킨후 투여한다.end. Constriction is added to the corpus cavernosum smooth muscle and then administered.
나. 수축제로 수축시킨 상태에서의 장력을 100으로 하였을 때 장력이 몇 % 까지 감소되었는지 측정한다.I. When the tension in the contracted state with the shrinkage agent is 100, it is measured how many percent the tension is reduced.
2)실험결과2) Experiment result
(1) 음경해면체 평활근에 대한 이완효과(1) Relaxation effect on corpus cavernosum smooth muscle
(2) 시험결과 본 발명의 기능성식품이 발기부전에 효과가 있음을 알 수 있다.(2) The test results show that the functional food of the present invention is effective in erectile dysfunction.
· 상기 실험 예를 통하여 설명한 바와 같이 본 발명은 남성 성기능 장애에 효과가 있어 성신경 과민증 성생활 산업상 매우 유용한 발명인 것이다.As described through the above experimental example, the present invention is effective for male sexual dysfunction and is a very useful invention for sexual hypersensitivity sexual life industry.
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020020038089A KR20040003401A (en) | 2002-07-02 | 2002-07-02 | Preparation and it's method of functional food for male sexual dysfunction |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020020038089A KR20040003401A (en) | 2002-07-02 | 2002-07-02 | Preparation and it's method of functional food for male sexual dysfunction |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20040003401A true KR20040003401A (en) | 2004-01-13 |
Family
ID=37314410
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020020038089A KR20040003401A (en) | 2002-07-02 | 2002-07-02 | Preparation and it's method of functional food for male sexual dysfunction |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20040003401A (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005115426A1 (en) * | 2004-05-31 | 2005-12-08 | Wakunaga Pharmaceutical Co., Ltd. | Drug for ameliorating male climacteric disorder |
JP2006306889A (en) * | 2004-05-31 | 2006-11-09 | Wakunaga Pharmaceut Co Ltd | Drug for ameliorating male climacteric disorder |
JP2007084559A (en) * | 2004-05-31 | 2007-04-05 | Wakunaga Pharmaceut Co Ltd | Blood testosterone level-lowering inhibitor |
-
2002
- 2002-07-02 KR KR1020020038089A patent/KR20040003401A/en not_active Application Discontinuation
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005115426A1 (en) * | 2004-05-31 | 2005-12-08 | Wakunaga Pharmaceutical Co., Ltd. | Drug for ameliorating male climacteric disorder |
JP2006306889A (en) * | 2004-05-31 | 2006-11-09 | Wakunaga Pharmaceut Co Ltd | Drug for ameliorating male climacteric disorder |
JP2007084559A (en) * | 2004-05-31 | 2007-04-05 | Wakunaga Pharmaceut Co Ltd | Blood testosterone level-lowering inhibitor |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103735838B (en) | One breeding kidney health care medicinal liquor for tonifying kidney and preparation method thereof | |
CN100356935C (en) | Formulations useful in the treatment of male and female impotence | |
CN109316528B (en) | Medicine for treating male erectile dysfunction and preparation method thereof | |
CN104288461A (en) | Ginseng cornu cervi tea traditional Chinese medicine decoction piece combined preparation, as well as preparation method and combined package thereof | |
KR101189108B1 (en) | A composition containing dendropanax morbifera extract for improving sexual function | |
CN108277138A (en) | A kind of health-care and nutritious wine and preparation method thereof | |
JP2017513822A (en) | Composition for prevention, treatment and amelioration of dysuria including Indian Pepper extract | |
CN110521844A (en) | Deer fibrous-root ginseng product pressed candy and preparation method thereof | |
CN106511762B (en) | Maca health-care wine capable of tonifying kidney and strengthening yang and preparation method thereof | |
CN103446341A (en) | Traditional Chinese medicine composition for yang and kidney tonifying and health care and method for preparing same | |
KR20040003401A (en) | Preparation and it's method of functional food for male sexual dysfunction | |
KR100850503B1 (en) | Composition for improving erectile dysfunction and erection maintenance containing the extract of crude drug complex | |
CN104491310B (en) | Anti-Fatigue Composition and its preparation method and application | |
CN113456778A (en) | Composition for improving energy and preparation method thereof | |
KR20050048940A (en) | Composition comprising a magnesium compound and/or a magnesium salt for improving sexual dysfunction | |
CN109718304A (en) | Improve the Chinese medicine composition of the microcirculation of human body cardio and vascular function and pre- preventing thrombosis | |
CN109718305A (en) | Improve energy and blood of human body function and improves the Chinese medicine composition that resist oxygen lack delays senescence | |
KR101113978B1 (en) | Composition for improving erectile dysfunction and erection maintenance comprising the extract of Polygala tenuifolia as an active ingredient | |
KR20090013956A (en) | Composition for improving erectile dysfunction and erection maintenance comprising the extract of crude drug complex | |
KR100692173B1 (en) | Health functional food having an energetic and sturdy action | |
CN105169129A (en) | Zhuang medicine composition for treating hypertension and preparation method thereof | |
KR101024611B1 (en) | Composition for improving erectile dysfunction and erection maintenance comprising the extract of Nelumbinis Semen | |
CN116114778A (en) | Food composition for promoting testosterone level and preparation method thereof | |
KR20060114484A (en) | Healthy food for building up sexal potential and their manufacturing method | |
KR20040034328A (en) | The Product for Improving the Impotence with Mixtures of Red Ginseng and Natural Substances, and Including Food Theirof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |